Rx License-Rx

15-7389-tpNCS

Human Monoclonal Autoantibodies to ADAMTS13 and Uses Thereof

Human anti-ADAMTS13 antibodies cloned from patients with acquired thrombotic thromobocytopenia purpura (TTP) for use in targeted therapies, and generation of animal models that recapitulate pathologic features of TPP. Applications: Development of more effective, targeted therapies for TTP, such as anti-idiotypic agents Generation of improved animal models of TTP that permits testing of therapeutics targeting human antibody/ADAMTS13 interaction Inventors: Eric Ostertag, Donald Siegel, X. Long Zheng.

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Immunology

Indication:

Modality: Biologic

Focus tags: Immunology, Rare Disease, Infectious Disease

Technology tags: Biologic, Diagnostic / Biomarker, Cell/Gene Therapy

Mechanism:

Development stage: Preclinical

Patent status: US 11,597,778

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Immunology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is a resistant-pathogen niche with high unmet need and grant leverage. Public description: Human anti-ADAMTS13 antibodies cloned from patients with acquired thrombotic thromobocytopenia purpura (TTP) for use in targeted therapies, and generation of animal models that recapitulate pathologic features of TPP. Applications.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

First indication is not obvious: A broad use case can waste capital. The license needs one narrow patient segment or buyer problem before development starts.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Immunology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: a resistant-pathogen niche with high unmet need and grant leverage

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.